|

iCAGES-guided Precision Therapy for Cancers in Contrast to Standard Care or IHC-guided Theray

RECRUITINGSponsored by Second Affiliated Hospital of Guangzhou Medical University
Actively Recruiting
SponsorSecond Affiliated Hospital of Guangzhou Medical University
Started2017-07-01
Est. completion2030-07-01
Eligibility
Age18 Years – 70 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT03192501

Summary

This study prospectively evaluates whether the use of iCAGES (integrated CAncer GEnome Score) tool in guiding the treatment of advanced cancers is superior to current standard care or IHC-guided therapy in progress free survival (PFS),overall survival (OS),and improvement of life quality.

Eligibility

Age: 18 Years – 70 YearsHealthy volunteers accepted
Inclusion Criteria:

* Pathological and clinical diagnosis of recurrence / metastatic lung cancer or other advanced cancers.
* There are PACS images available at the Second Affiliated Hospital of Guangzhou Medical University and the collaborated Hospitals.
* The patient is informed consent and signed a written consent.

Exclusion Criteria:

* Age \> 70 or \<18 years old.
* Previous history of malignant tumors.
* Pregnant or lactating female patients.
* Any serious concomitant disease that is expected to have an adverse effect on prognosis, including the heart disease that treatment is required, unsatisfactory controlled diabetes and psychiatric disorders.

Conditions4

CancerGene AbnormalityGene Product Sequence VariationLung Cancer

Browse More Trials

Cancer trialsLung Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.